Cardiovascular Issues in Hematopoietic Stem Cell Transplantation (HSCT)

Opinion Statement Hematopoietic stem cell transplantation (HSCT) is considered, since 1957, a potentially curative therapeutic option for many hemopathies. Although it is an aggressive procedure, improvements in transplantation techniques and supportive strategies have markedly decreased treatment-related mortality, and the prevalence of HSCT survivors is expected to exceed half a million by 2030. At the same time, there is a growing awareness of the potentially negative effects of HSCT-related therapies on the cardiovascular (CV) system, and HSCT survivors constitute a population at high cardiovascular (CV) risk. Cardio-oncology has been proposed as a new approach to prevent cardiovascular toxicity during and after HSCT. The present article attempts to provide a multidisciplinary and practical approach to the prevention, monitoring, and management of the most common cardiovascular complications in patients undergoing hematopoietic stem cell transplantation.

Automated summary

Hematopoietic stem cell transplantation is considered a potentially curative option for many hemopathies since 1957, but survivors are at high cardiovascular risk. Advancements in techniques and strategies have reduced treatment-related mortality, leading to a growing number of HSCT survivors anticipated to exceed half a million by 2030.